Leukemia Research
Volume 33, Issue 9 , Pages 1194-1198 , September 2009

Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients

  • Lin Li

      Affiliations

    • The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
    • ,
  • Xu-Ping Liu

      Affiliations

    • Laboratory of Cytogenetics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
    • ,
  • Ling Nie

      Affiliations

    • The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
    • ,
  • Ming-Hua Yu

      Affiliations

    • Laboratory of Morphology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
    • ,
  • Yue Zhang

      Affiliations

    • Department of Clinical Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academe of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
    • ,
  • Tie-Jun Qin

      Affiliations

    • Department of Clinical Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academe of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
    • ,
  • Zhi-Jian Xiao

      Affiliations

    • The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
    • Department of Clinical Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academe of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
    • Corresponding Author InformationCorresponding author at: Department of Clinical Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, 288 Nanjing Road, Tianjin 300020, China. Tel.: +86 22 23909184; fax: +86 22 27219070.

Received 8 October 2008 ,Revised 19 November 2008 ,Accepted 24 November 2008.

References 

  1. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007;31:727–736
  2. Bernasconi P, Klersy C, Boni M, et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol. 2007;137:193–205
  3. Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 2005;19:767–775
  4. Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood. 2005;106:2633–2640
  5. Lee JH, Lee JH, Shin YR, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia. 2003;17:305–313
  6. Intragumtornchai T, Prayoonwiwat W, Swasdikul D, et al. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leuk Res. 1998;22:453–460
  7. Vardiman JW, Harris NL, Brunning RD, et al. The Wor1d Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  8. Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  9. Olney HJ, Le Beau MM. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res. 2007;31:427–434
  10. Virtaneva K, Writht FA, Tanner SM, et al. Expression profiling reveal fundamental biological differences in acute myeloid leukemia with isolated trosomy 8 and normal cytogenetics. PNAS. 2001;98:1124–1129
  11. Xiao Z, Liu Z, Yu M, et al. Ischromosome 17q in patients with myelodysplastic syndromes: six new cases. Haematologica. 2003;88:714–715
  12. Xiao Z, Zhang M, Liu X, et al. MEL1s, not MEL1, is overexpressed in myelodysplastic symdromes patients with t(1;3)(p36;q21). Leuk Res. 2006;30:332–334
  13. Pfeilstöcker M, Reisner R, Nösslinger T, et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol. 1999;106:455–463
  14. Belli C, Acevedo S, Bengio R, et al. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Haematologica. 2002;87:9–16
  15. Lorand-Metze I, Pinheiro MP, Ribeiro E, et al. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res. 2004;28:587–594
  16. Müller-Berndorff H, Haas PS, Kunzmann R, et al. Comparison of five prognostic scoring systems, the French–American–British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol. 2006;85:502–513
  17. Navarro I, Ruiz MA, Cabello A, et al. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. Leuk Res. 2006;30:971–977

PII: S0145-2126(08)00523-7

doi: 10.1016/j.leukres.2008.11.021

Leukemia Research
Volume 33, Issue 9 , Pages 1194-1198 , September 2009

Article Tools

* Image Usage & Resolution